Project description:This SuperSeries is composed of the following subset Series:; GSE15389: Peripheral blood mononuclear cells treated with a CDK inhibitor; GSE15392: DU145 tumor cells treated with a CDK inhibitor; GSE15395: HCT116 tumor cells treated with a CDK inhibitor Experiment Overall Design: Refer to individual Series
Project description:The limited benefit of immune checkpoint inhibitor in breast cancer indicates the pressing need to identify biomarkers of response to minimize risk and maximize benefit. In this study, we performed single cell RNA sequencing and T cell receptor sequencing on peripheral blood mononuclear cells to monitor the peripheral immune dynamics of an exploratory cohort of hormone receptor positive breast cancer patients treated with neoadjuvant nab-paclitaxel+pembrolizumab with the ultimate goal of identifying potential peripheral blood predictive biomarkers.
Project description:To investigate differential protein and phospho-protein changes in the signaling cascades related to mutant G2019S LRRK2 using peripheral blood mononuclear cells (PBMCs)
Project description:We report RNA-sequencing analysis of human peripheral blood mononuclear cells exposed to clinically recommended doses (500 nM) of the HSP90 inhibitor ganetispib. Global analysis of the expression profiles of treated cells revealed wide spread changes in gene expression, specifically, upregulation of protein folding and assembly pathways, with downregulation of antigen presentation through MHC Class I and Class I.